SEC Form 10-Q Summary
Filing identity: The provided filing is for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc. It covers the unaudited quarter ended March 31, 2016 and was filed May 16, 2016.
Business Context and Reporting Period
Zeta Acquisition Corp. II is a Delaware shell and blank-check company formed to identify and complete a business combination with an operating company. It has generated no revenue since inception and had not identified or held discussions with a potential target as of the filing date. The company reported 5,000,000 common shares outstanding as of May 16, 2016.
Financial Position and Results
| Metric | Three Months Ended March 31, 2016 | Three Months Ended March 31, 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $3,962 | $3,962 |
| Interest expense | $2,394 | $1,853 |
| Net loss | $6,356 | $5,815 |
| Net loss per basic and diluted share | $0.00 loss | $0.00 loss |
| Cash used in operating activities | $5,300 | $1,976 |
| Cash provided by financing activities | $0 | $20,000 |
| Ending cash and cash equivalents | $13,229 | $23,287 |
At March 31, 2016, cash and total assets were $13,229, compared with $18,529 at December 31, 2015. Total liabilities were $206,066, including $160,000 of notes payable to stockholders, $34,830 of accrued interest, $8,036 of accounts payable, and $3,200 of accrued expenses. Stockholders’ deficit was $192,837.
The company has no operating margins to report because it has no revenue. Its debt consists primarily of unsecured stockholder notes bearing 6% interest and payable on demand. Accrued interest on these notes totaled $34,830 at March 31, 2016.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $541, or approximately 9%, from $5,815 to $6,356, primarily because interest expense increased.
- Operating cash use increased by $3,324, from $1,976 to $5,300.
- The prior-year quarter included $20,000 of stockholder-note financing; no financing proceeds were received in the current quarter.
- Ending cash declined by $10,058, or approximately 43%, from $23,287 to $13,229.
- Accounts payable increased from $3,674 to $8,036, while accrued expenses decreased from $8,900 to $3,200.
Outlook, Risks, Contingencies, and Unusual Items
Management plans to continue searching for a suitable acquisition candidate and expects to incur costs for SEC reporting and evaluating and completing a potential acquisition. Management expects funding may come from existing cash, deferred service-provider fees, stockholder or management loans, equity financing, or a reverse-merger transaction, but states that additional funding is not assured.
The financial statements include a going-concern disclosure. The company has incurred an accumulated deficit of $242,837, depends on financing and related-party funding, has nominal assets, and cannot assure that it can satisfy cash requirements for at least the next twelve months. Failure to obtain funding or complete a business combination could prevent continuation of operations.
Potential acquisition targets may be financially unstable, early-stage, or operating in high-risk industries. The company expects it may complete only one business combination, creating concentration and diversification risk. The filing reports no material legal proceedings, no off-balance-sheet arrangements, no unregistered securities sales, and no defaults upon senior securities.
Approximately $82,600 of deferred tax assets were fully offset by a valuation allowance because realization of the related tax benefits was uncertain. Office space and equipment are provided by an officer and director at no cost on a month-to-month basis; management considers the amounts de minimis. Management concluded that disclosure controls and procedures were effective as of March 31, 2016.
Investor Verification Items
- Verify the issuer’s identity: the supplied filing is for Zeta Acquisition Corp. II rather than Whitehawk Therapeutics, Inc.
- Confirm the company’s ability to obtain additional financing and continue as a going concern.
- Review the $160,000 of stockholder notes, their demand repayment terms, and the $34,830 of accrued interest.
- Assess whether and when a business combination could occur; the filing provides no committed transaction or specific target.
- Reconcile the sharp decline in cash and the increase in operating cash use against the company’s limited current assets and substantial liabilities.
- Consider dilution and concentration risks associated with a potential reverse merger or equity financing.